Hypereosinophilic Syndrome End Organ Score

Assess end-organ damage in hypereosinophilic syndrome across cardiac, neurologic, pulmonary, GI, and dermatologic systems to stratify treatment urgency with corticosteroids or mepolizumab.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Assess end-organ damage in hypereosinophilic syndrome across cardiac, neurologic, pulmonary, GI, and dermatologic systems to stratify treatment urgency with corticosteroids or mepolizumab

Each component has a specific meaning:

  • Cardiac — The cardiac recorded for the scenario being assessed.
  • Neurologic — The neurologic recorded for the scenario being assessed.
  • Pulmonary — The pulmonary recorded for the scenario being assessed.
  • GI — The gi recorded for the scenario being assessed.
  • Dermatologic systems — The dermatologic systems recorded for the scenario being assessed.

Note: Interpret the hes end organ score result against the thresholds and context described above.

How to Use

Enter the cardiac, neurologic, pulmonary, GI, dermatologic systems for the scenario you are assessing. Assess end-organ damage in hypereosinophilic syndrome across cardiac, neurologic, pulmonary, GI, and dermatologic systems to stratify treatment urgency with corticosteroids or mepolizumab. Use the hes end organ score result to inform your calculation.

Frequently Asked Questions